Yale University

Deutsches Krebsforschungszentrum

The Royal Institution for the Advancement of Learning / Mcgill University

Universitatsklinikum Heidelberg

German Cancer Research Center (dkfz)

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

German Cancer Research Center

Peter Lichter

David C Ward

Thomas Ried

Thomas Cremer

Laura Manuelidis

Peter Angel

Marina Schorpp-Kistner

Stefan M Pfister

Anna Jauch

Michael Speicher

Antonio Baldini

Susanne Stumm

Alexander Marme

Gunnar Wrobel

Guido Reifenberger

Sabine Gack

Nada Jabado

Christoph Plass

Andrey Korshunov

Hendrik Witt

Dominik Sturm

David Jones

Elke Pfaff

Bernhard Radlwimmer

Martje Toenjes

Sebastian Barbus

Armin Pscherer

Daniel Mertens

Stefan Joss

Stephan Wolf

Grischa TÖDT

Martje TÖNJES

Martje Tonjes

The present application shows the relationship between variations in the amino acid sequence of histone proteins, more specifically the H3.3 protein, and proliferation-associated disorders. Herewith provided are predictive methods, commercial packages, therapeutic methods and screening methods based on this relationship.

Mutations of histone proteins associated with proliferative disorders

Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotranferase-1 (BCAT1) or (b) the expression of the gene encoding BCAT1 for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl) cyclohexaneacetic acid (gabapentin).

Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of brain tumors

The present invention relates to the significant role of ADAM 12, ADAM 12-L, and ADAM 12-S in preeclampsia and related disorders. The invention further relates to the use of said genes and gene products, ligands binding to those, and modulators of activity of the gene products in diagnosis and treatment of preeclampsia and related syndromes. The invention also relates to the use of further genes and combinations thereof in diagnosis of preeclampsia and related syndromes.

Use of ADAM 12 for diagnosis and therapy of preeclampsia

This disclosure relates to a method of specifically decorating selected mammalian chromosomes and of detecting, identifying and and/or quantitating selected individual chromosomes, by means of chromosomal in situ suppression (CISS) hybridization. The method is useful in analyzing cells for the occurrence of chromosomes, chromosome fragments or chromosome aberrations.

Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization

A method of determining the relative number of nucleic acid sequences in test cells which provides for a high resolution during comparative genomic hybridization by keeping all components separate from each other and selecting target nucleic acids which have a high resolution capability for determining genomic imbalances in the test cells and which facilitate a screening of the test cells for over- or under-expression of individual genes.

Arrangement of nucleic acid sequences for comparative genomic hybridization

A method is disclosed for determining the chromosomal identity of a sample of genomic DNA. The genomic DNA is amplified and labeled by polymerase chain reaction using primers substantially complementary to interspersed repetitive DNA sequences. The amplified and labeled genomic DNA fragments are then contacted with chromosomal DNA of known identity under conditions in which the chromosome-specific, but not the interspersed repetitive DNA sequences, of the amplified and labeled genomic DNA fragments are available for hybridization. Specific hybridization to chromosomal DNA of known identity determines the chromosomal identity of the sample of genomic DNA.

Amplification karyotyping

Growing community of inventors

Gaiberg, Germany

Peter Lichter